Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials

Simple item page
dc.contributor.authorWang, Ten_US
dc.contributor.authorWu, Wen_US
dc.contributor.authorZhang, Xen_US
dc.contributor.authorGan, Ben_US
dc.contributor.authorZhou, Yen_US
dc.contributor.authorCheng, X.en_US
dc.date.accessioned2025-06-18T11:42:21Z
dc.date.available2025-06-18T11:42:21Z
dc.date.issued2025-04
dc.description.abstractObjectives: Tofacitinib is used as an oral Janus-associated kinase (JAK) inhibitor acting on JAK1 and JAK3, in treating psoriatic disease. However, there is still no consensus on the optimal dosage and duration of tofacitinib. In this study, we aimed to evaluate the effects of tofacitinib in treating psoriatic disease. Methods: A literature search was done utilising Cochrane library, Medline, EMBASE, Wiley Online library, Web of Science and BIOSIS Previews through December 18, 2022. We performed a meta-analysis of published original studies to assess the impact of tofacitinib in plaque psoriasis or psoriatic arthritis therapy based on seven randomised controlled trials (RCTs) involving 2,672 patients (receiving tofacitinib) and 853 controls (receiving placebo). Results: Compared with placebo, the treatment of 5 mg twice-daily (BID) tofacitinib for 12 weeks is sufficient to significantly alleviate the main clinical manifestations of psoriasis [?75% decrease in Psoriasis Area and Severity Index score (PASI 75): Risk ratio (RR)=4.38 (95% Confidence interval (CI) 2.51 to 7.64); ?90% decrease in PASI score (PASI 90): RR=21.68 (95% CI 4.20 to 111.85); Physician’s Global Assessment of ‘clear’ or ‘almost clear’ (PGA 0/1): RR=3.93 (95%CI 3.03 to 5.09)]. Interestingly, there was no significant difference in improvement in PGA 0/1 with 5 mg BID tofacitinib given for 16 weeks when compared with 5 mg BID tofacitinib for 12 weeks [RR=1.11 (95%CI 0.98 to 1.25)]. Additionally, the 5 mg BID tofacitinib for 16 weeks treatment schedule significantly increased the incidence of upper respiratory tract infection (URTI) [RR=1.89 (95%CI 1.06 to 3.38)] as compared to 5 mg BID tofacitinib for 12 weeks treatment schedule [RR=1.15 (95%CI 0.60 to 2.20)]. Conclusion: The 5 mg BID tofacitinib for 12 weeks treatment significantly improved psoriasis without causing too many specific adverse events. This indicated that tofacitinib is an effective treatment plan for psoriatic disease by reasonably controlling dosage and dosing time.en_US
dc.identifier.affiliationsDepartment of Sexual Medicine/Traditional Chinese Medicine, Fifth People’s Hospital of Shunde District (Longjiang Hospital of Shunde District), Foshan, Guangdong, Chinaen_US
dc.identifier.affiliationsDepartment of Medical Science, Shunde Polytechnic, Foshan, Guangdong, Chinaen_US
dc.identifier.affiliationsDepartment of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, Chinaen_US
dc.identifier.affiliationsDepartment of Respiratory Medicine, Fifth People’s Hospital of Shunde District (Longjiang Hospital of Shunde District), Foshan, Guangdong, Chinaen_US
dc.identifier.affiliationsDepartment of Basic Medical Sciences, Guangdong Medical University, Dongguan, Guangdong, Chinaen_US
dc.identifier.affiliationsDepartment of Traditional Chinese Medicine, The Second Clinical Medical College, Guangdong Medical University, Dongguan, Guangdong, Chinaen_US
dc.identifier.citationWang T, Wu W, Zhang X, Gan B, Zhou Y, Cheng X.. Tofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trials. Indian Journal of Dermatology, Venereology and Leprology. 2025 Apr; 91(2): 172-179en_US
dc.identifier.issn0378-6323
dc.identifier.issn0973-3922
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/249389
dc.languageenen_US
dc.publisherScientific Scholar on behalf of Indian Association of Dermatologists, Venereologists & Leprologists (IADVL), India.en_US
dc.relation.issuenumber2en_US
dc.relation.volume91en_US
dc.source.urihttps://dx.doi.org/10.25259/IJDVL_14_2024en_US
dc.subjectAdverse drug eventsen_US
dc.subjectefficacyen_US
dc.subjectplaque psoriasisen_US
dc.subjectpsoriatic arthritisen_US
dc.subjecttofacitiniben_US
dc.titleTofacitinib treatment for plaque psoriasis and psoriatic arthritis: A meta-analysis of randomised controlled trialsen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
ijdvl2025v91n2p172.pdf
Size:
2.85 MB
Format:
Adobe Portable Document Format
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology